Importantly, by combining both elements of CDK4/6 response, it is possible to parse the current proliferative/non-proliferative subtypes into additional prognostic groups that could have significance in assessing risk of recurrence in ER+/HER2- breast cancer. This evidence concerns the gene ESR1 and breast cancer.